Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma

BACKGROUND: Prognostic factors for progression-free survival (PFS), overall survival (OS), and long-term OS (⩾30 months) were investigated in sunitinib-treated patients with metastatic renal cell carcinoma (RCC). METHODS: Data were pooled from 1059 patients in six trials. Baseline variables, includi...

Descripción completa

Detalles Bibliográficos
Autores principales: Motzer, R J, Escudier, B, Bukowski, R, Rini, B I, Hutson, T E, Barrios, C H, Lin, X, Fly, K, Matczak, E, Gore, M E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694236/
https://www.ncbi.nlm.nih.gov/pubmed/23695024
http://dx.doi.org/10.1038/bjc.2013.236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694236/
https://www.ncbi.nlm.nih.gov/pubmed/23695024
http://dx.doi.org/10.1038/bjc.2013.236

Ejemplares similares